CureVac (NASDAQ:CVAC) Shares Gap Up to $2.94

CureVac (NASDAQ:CVAC)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $2.94, but opened at $3.05. CureVac shares last traded at $2.92, with a volume of 88,991 shares.

CureVac Trading Down 0.7 %

The firm has a 50-day moving average of $3.40 and a 200 day moving average of $4.80. The company has a current ratio of 3.56, a quick ratio of 3.41 and a debt-to-equity ratio of 0.06.

Hedge Funds Weigh In On CureVac

Several hedge funds and other institutional investors have recently bought and sold shares of CVAC. Price T Rowe Associates Inc. MD increased its holdings in CureVac by 588.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,813,896 shares of the company’s stock worth $26,583,000 after purchasing an additional 3,260,031 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in CureVac during the 1st quarter worth approximately $7,391,000. BlackRock Inc. increased its holdings in CureVac by 62.8% during the 1st quarter. BlackRock Inc. now owns 1,972,937 shares of the company’s stock worth $13,751,000 after purchasing an additional 761,024 shares during the last quarter. Norges Bank purchased a new stake in CureVac during the 4th quarter worth approximately $2,960,000. Finally, Millennium Management LLC increased its holdings in CureVac by 61.6% during the 4th quarter. Millennium Management LLC now owns 866,244 shares of the company’s stock worth $5,223,000 after purchasing an additional 330,212 shares during the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.